Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 3Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 2Other solid neoplasm 1Gynecologic 1

Conditions

Glioblastoma 2Ovarian Neoplasms 1Glioma 1Advanced Malignant Solid Neoplasm 1Advanced Malignancies 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
pamiparib × 90 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

NCT04614909 2026-05-14

Study of Pamiparib in Newly Diagnosed and rGBM

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Completed
50 enrolled
CNS

Glioblastoma

NCT05038839 2026-05-12

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
44 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

BeOne Medicines

Phase 3 Active not recruiting
224 enrolled
Gynecologic

Ovarian Neoplasms

NCT03749187 2026-03-13

PNOC017

University of California, San Francisco

Phase 1 Active not recruiting
78 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡